Merck KGaA to Open $326 Million Pharmaceutical Plant in South Korea to Expand in Asia
By David Sachs
Merck KGaA will spend more than 300 million euros ($326 million) on a pharmaceutical plant in South Korea as part of its strategy to expand in Asia.
The German drug-and-chemicals company said Wednesday that the plant will add 300 jobs. The Daejeon facility will serve biotech and pharmaceutical companies that develop, research and manufacture medical treatments like vaccines and cell, gene, and protein-based therapies, Merck said.
The production site will bring the firm closer to customers in an expanding market and should speed up the process of bringing new treatments from the development phase to commercialization, the firm said. Merck's investment is the largest to date by its life-sciences division in the Asia-Pacific region.
Write to David Sachs at david.sachs@wsj.com
(END) Dow Jones Newswires
March 20, 2024 11:42 ET (15:42 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Powell Unfazed By Sticky Inflation, but Rate Cuts Are Far Off
-
After Earnings, Is Microsoft Stock a Buy, a Sell, or Fairly Valued?
-
Best- and Worst-Performing Stocks of April 2024
-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
Small-Cap and Value Stocks Are Undervalued
-
Why We Expect the Job Market’s Slowdown to Renew in 2024
-
5 Undervalued Stocks to Buy to Play a Little Defense
-
10 Top-Performing Dividend Stocks of the Month
-
Marathon Petroleum Earnings: No Change to Competitive Position, but Shares Look Expensive
-
Charlie Munger and How Not to Invest
-
Look Inside Berkshire Hathaway’s Portfolio Before Its Annual Meeting
-
After Earnings, Is AT&T Stock a Buy, a Sell, or Fairly Valued?
-
Mastercard Earnings: A Stable Environment Highlights the Firm’s Strengths
-
Pfizer Earnings: Solid Results Supported by Steady Tracking Toward $4 Billion In Cost Cuts
-
Starbucks Earnings: Not a Lot to Like About Results as Global Traffic Sputters